Download PDF
Dtsch Med Wochenschr 2013; 138(S 01): S4-S6
DOI: 10.1055/s-0032-1305325
Editorial
Diabetologie, Pharmakotherapie
© Georg Thieme Verlag KG Stuttgart · New York

SGLT-2-Inhibitor Dapagliflozin: Neuer Therapieansatz für den Typ-2-Diabetes, neue Erfolge, aber auch neue Fragen!

SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2 – new achievements, but also new questions!
M. Nauck
1   Diabeteszentrum Bad Lauterberg
,
S. Del Prato
2   Abteilung Diabetes und Metabolische Störungen, Institut für Endokrinologie und Stoffwechsel, Universität Pisa, Italien
› Author Affiliations
Further Information

Publication History

31 July 2012

09 August 2012

Publication Date:
25 March 2013 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Dapagliflozin - Typ-2-Diabetes - SGLT-2-Inhibitoren

Keywords

dapagliflozin - type 2 diabetes - SGLT-2-inhibitors
 

  • Literatur

  • 1 Nauck MA, Del Prato S, Meier JJ et al. Dabagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin. A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022
    CrossrefPubMedGoogle Scholar
  • 2 Strojek K, Yoon KH, Hruba V et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadeqquate glycaemic control with glimepiride: a rondomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-938
    CrossrefPubMedGoogle Scholar
  • 3 Wilding JPH, Woo V, Soler NG et al. Long-term efficacy of dapagliflozin in patient with type 2 diabetes mellitus receiving high dose of insulin. Ann Intern Med 2012; 156: 405-415
    CrossrefPubMedGoogle Scholar